Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.
Effects of atorvastatin and pravastatin on glucose tolerance in mildly induced diabetic rats by streptozotocin at 24 mg/kg, i.v. were studied. Non-diabetic and diabetic rats were given orally 0.5% carboxymethylcellulose (control), 8 mg/kg atorvastatin or 8 mg/kg pravastatin once a day for 6 weeks. An oral glucose tolerance test (OGTT) was carried out 1, 2, 3, and 6 weeks after the administration. The blood glucose and plasma insulin levels measured before OGTT in the diabetic rats were not different from those in the non-diabetic rats. However, the hyperglycemic response to OGTT in the diabetic rats significantly exceeded that in the non-diabetic rats. The plasma insulin increased by OGTT in the diabetic rats appeared to be lower than that in the non-diabetic rats. Statin treatments for 1 week did not modify the OGTT-induced hyperglycemia appreciably, although there were some significant differences. More than 2 weeks after administration, the blood glucose levels at several time points after a glucose intake in the atorvastatin-treated diabetic rats were significantly higher than the respective levels in the control diabetic rats. Neither atorvastatin nor pravastatin modified the OGTT-induced insulin secretion. Statins, especially atorvastatin, may influence the glucose tolerance in mildly induced diabetic rats without alterations of insulin secretion.
Kanda
Makoto
M
Department of Pharmacology, Hokkaido College of Pharmacy, Katsuraoka, Otaru, Japan.
Satoh
Kumi
K
Ichihara
Kazuo
K
D000284:Administration, Oral; D000818:Animals; D000069059:Atorvastatin; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005947:Glucose / Q000008:administration & dosage; D005951:Glucose Tolerance Test / Q000009:adverse effects* / Q000379:methods; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007275:Injections, Intravenous; D007328:Insulin / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D017035:Pravastatin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011758:Pyrroles / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D001786:Blood Glucose; D006538:Heptanoic Acids; D007328:Insulin; D011758:Pyrroles; D013311:Streptozocin; D000069059:Atorvastatin; D005947:Glucose; D017035:Pravastatin